A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pliant Therapeutics, Inc.
OncoC4, Inc.
Genmab
Sotio Biotech Inc.
Dragonfly Therapeutics
PMV Pharmaceuticals, Inc
NeoImmuneTech
Merck Sharp & Dohme LLC
Tizona Therapeutics, Inc
BioInvent International AB
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Novartis
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
BicycleTx Limited
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Toray Industries, Inc
Medicenna Therapeutics, Inc.
OncoC4, Inc.
Compugen Ltd
Carisma Therapeutics Inc
NextCure, Inc.
Five Prime Therapeutics, Inc.
Sellas Life Sciences Group
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
ADC Therapeutics S.A.
Sumitomo Pharma America, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Stingthera, Inc.
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
Tesaro, Inc.
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC